Log in

Relevant bibliographies by topics / Measles-Mumps-Rubella Vaccine $$x adverse effects

Contents

Journal articles
Dissertations / Theses
Books

Academic literature on the topic 'Measles-Mumps-Rubella Vaccine $$x adverse effects'

Author: Grafiati

Published: 4 June 2021

Last updated: 1 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Measles-Mumps-Rubella Vaccine $$x adverse effects.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Measles-Mumps-Rubella Vaccine $$x adverse effects"

1

Ogawa, Taku, Fukumi Uchiyama-Nakamura, Aiko Sugata-Tsubaki, Yutaka Yamada, Kenji Uno, Kei Kasahara, Koichi Maeda, Mitsuru Konishi, and Keiichi Mikasa. "Antibody Response to Live Attenuated Vaccines in Adults in Japan." Open Medicine 11, no. 1 (January 1, 2016): 482–88. http://dx.doi.org/10.1515/med-2016-0085.

Full text

Abstract:

AbstractThe purpose of this study was to examine the efficacy rendered with a single dose of live attenuated measles, rubella, mumps, and varicella containing vaccine.We inoculated healthcare workers (HCWs) with a single dose of vaccine to a disease lacking in antibody titer for those not meeting the criteria of our hospital (measles: <16.0 (IgG enzyme immunoassay (EIA)), rubella: ≤1:32 (hemagglutination-inhibition), mumps: <4.0 (IgG EIA), and varicella: <4.0 (IgG EIA)). At 28–60 days after vaccination, the antibody titer was tested again.We included 48 HCWs. A total of 32, 15, 31, and 10 individuals were inoculated with a single dose of measles-containing, rubella-containing, mumps, or varicella vaccine, respectively, and showed significant antibody elevation (9.2 ± 12.3 to 27.6 ± 215.6, p<0.001; 8 ± 1.2 to 32 ± 65.5, p<0.001; 3.0 ± 1.0 to 13.1 ± 8.6, p<0.05; and 2.6 ± 1.3 to 11.8 ± 8.1, p<0.001, respectively). Major side effects were not observed.In a limited population, a single dose of live attenuated vaccine showed elevation of antibody titer without any severe adverse reactions. However, whether the post-vaccination response rate criteria of our university was fulfilled could not be determined owing to limited sample size.

APA, Harvard, Vancouver, ISO, and other styles

2

K., Geetha. "Therapeutic evaluation of intralesional measles, mumps and rubella vaccine in palmoplantar warts." International Journal of Research in Dermatology 5, no. 4 (October 21, 2019): 827. http://dx.doi.org/10.18203/issn.2455-4529.intjresdermatol20194676.

Full text

Abstract:

<p class="abstract"><strong>Background:</strong> Warts are common viral infections of the skin caused by human papilloma virus. Most of the treatment modalities for common warts remain unsatisfactory. Immunotherapy has become one of the important therapeutic modality. This study was conducted to evaluate the efficacy of intralesional measles, mumps and rubella (MMR) vaccine immunotherapy in palmoplantar warts.</p><p class="abstract"><strong>Methods:</strong> 60 patients of various age groups and both sexes who have single or multiple palmoplantar warts not on any other concurrent systemic or topical therapy were randomly included for the study. Patients with other types of warts, signs of other infection, pregnancy, lactation and immunosuppression were excluded from the study. MMR Vaccine was injected intralesionally at 2 week intervals until complete clearance or for a maximum of 3 treatments. The outcome in terms of treatment relapse, recurrences and adverse effects were evaluated.<strong></strong></p><p class="abstract"><strong>Results:</strong> Only 54 patients completed the study and 41 (75.9%) of them showed complete response and 13 (24%) of them showed partial or no response.</p><p class="abstract"><strong>Conclusions:</strong> Intralesional MMR vaccine therapy appears to be a safe and effective treatment option with no significant adverse effects and low recurrence.</p>

APA, Harvard, Vancouver, ISO, and other styles

3

Rager-Zisman, Bracha, Elina Bazarsky, Agneta Skibin, Guy Tam, Shlomo Chamney, Ilana Belmaker, Iris Shai, Ella Kordysh, and Diane E. Griffin. "Differential Immune Responses to Primary Measles-Mumps-Rubella Vaccination in Israeli Children." Clinical Diagnostic Laboratory Immunology 11, no. 5 (September 2004): 913–18. http://dx.doi.org/10.1128/cdli.11.5.913-918.2004.

Full text

Abstract:

ABSTRACT Measles remains an important cause of morbidity and mortality worldwide, primarily due to problems associated with delivery of the live attenuated vaccine to susceptible populations. In some developed countries, there is concern about the effects of immunization on the immune system. In this study, we analyzed the responses of 12-month-old Bedouin and Jewish children living in Israel to routine measles-mumps-rubella (MMR) vaccination. Seroconversion to measles was 99% in Bedouin and 79% in Jewish children (P < 0.01), and that to mumps and rubella was 92 to 100% in both groups. Measles neutralizing antibody titers were higher in Bedouin (333 ± 39 mIU/ml) than Jewish (122 ± 60 mIU/ml) children (P < 0.002). Immunoglobulin G levels were higher in Bedouin than Jewish children (P = 0.007) and increased after vaccination (P = 0.0009). Leukocyte (P < 0.02) and lymphocyte (P = 0.04) counts were higher and CD4 lymphocyte percentages were lower (P < 0.001) in Bedouin than Jewish children before and after vaccination. Leukocyte counts and natural killer cell numbers did not change after vaccination, but lytic activity increased in Bedouin children (P < 0.005). Spontaneous proliferation of cultured peripheral blood mononuclear cells increased with vaccination, but there were no changes in the proliferative responses to phytohemagglutinin or tetanus toxoid. In summary, no adverse effects of MMR vaccination on immune function were detected. However, there were differences in underlying immunologic parameters and in response to the measles component of the vaccine between Bedouin and Jewish children. It is not known whether genetic differences or environmental exposure accounts for these differences.

APA, Harvard, Vancouver, ISO, and other styles

4

Bellavite, Paolo, and Alberto Donzelli. "Adverse events following measles-mumps-rubella-varicella vaccine: an independent perspective on Italian pharmacovigilance data." F1000Research 9 (September 28, 2020): 1176. http://dx.doi.org/10.12688/f1000research.26523.1.

Full text

Abstract:

Vaccine surveillance programs are crucial for the analysis of the vaccine’s safety profile and the guidance of health policies. The Epidemiological Observatory of the Italian Apulia Region carried out an active surveillance program of adverse effects following immunization (AEFI) after the first dose of the measles-mumps-rubella-varicella (MMRV) vaccine, finding 462 AEFIs per 1000 doses, with 11% rated serious. Applying the World Health Organization (WHO) causality assessment algorithm, 38 serious AEFIs/1000 enrolled were classified as ‘consistent causal associations’ with MMRV immunization. Severe hyperpyrexia, neurological symptoms and gastrointestinal diseases occurred in 38, 20 and 15 cases/1000 enrolled, respectively. A projection of such AEFIs in an Italian birth cohort would give tens of thousands of serious AEFIs. These incidence data are much greater than the incidence of serious AEFIs reported by the Italian Medicines Agency (AIFA) for years 2017 and 2018, mainly based on passive (or mixed) pharmacovigilance. In a previous epidemiological study in the same Italian Region, during an eight year passive surveillance, the reporting rate of serious AEFI was 0.06/1000 doses, and no cases of febrile seizures were detected applying the WHO algorithm. Taken together, the data suggest that passive pharmacovigilance is utterly inadequate to document the real incidence of serious AEFIs and that current methods of assessing causality may be questioned. Active surveillance programs are required in representative population samples, with results presented separately from those of spontaneous reporting, and causality assessment should be performed carefully and using a correct technique for AEFIs presenting as complex and multifactorial diseases, like those with serious neurologic disorders.

APA, Harvard, Vancouver, ISO, and other styles

5

Bellavite, Paolo, and Alberto Donzelli. "Adverse events following measles-mumps-rubella-varicella vaccine: an independent perspective on Italian pharmacovigilance data." F1000Research 9 (January 6, 2021): 1176. http://dx.doi.org/10.12688/f1000research.26523.2.

Full text

Abstract:

Vaccine surveillance programs are crucial for the analysis of the vaccine’s safety profile and the guidance of health policies. The Epidemiological Observatory of the Italian Apulia Region carried out an active surveillance program of adverse effects following immunization (AEFI) after the first dose of the measles-mumps-rubella-varicella (MMRV) vaccine, finding 462 AEFIs per 1000 doses, with 11% rated serious. Applying the World Health Organization (WHO) causality assessment algorithm, 38 serious AEFIs/1000 enrolled were classified as ‘consistent causal associations’ with MMRV immunization. Severe hyperpyrexia, neurological symptoms and gastrointestinal diseases occurred in 38, 20 and 15 cases/1000 enrolled, respectively. A projection of such AEFIs in an Italian birth cohort would give tens of thousands of serious AEFIs. These incidence data are much greater than the incidence of serious AEFIs reported by the Italian Medicines Agency (AIFA) for years 2017 and 2018, mainly based on passive (or mixed) pharmacovigilance. In a previous epidemiological study in the same Italian Region, during an eight year passive surveillance, the reporting rate of serious AEFI was 0.06/1000 doses, and no cases of febrile seizures were detected applying the WHO algorithm. Taken together, the data suggest that passive pharmacovigilance is utterly inadequate to document the real incidence of serious AEFIs and that current methods of assessing causality may be questioned. Active surveillance programs are required in representative population samples, with results presented separately from those of spontaneous reporting, and causality assessment should be performed carefully and using a correct technique for AEFIs presenting as complex and multifactorial diseases, like those with serious neurologic disorders.

APA, Harvard, Vancouver, ISO, and other styles

6

Omersel, Jasna, and Nataša Karas Kuželički. "Vaccinomics and Adversomics in the Era of Precision Medicine: A Review Based on HBV, MMR, HPV, and COVID-19 Vaccines." Journal of Clinical Medicine 9, no. 11 (November 5, 2020): 3561. http://dx.doi.org/10.3390/jcm9113561.

Full text

Abstract:

Precision medicine approaches based on pharmacogenomics are now being successfully implemented to enable physicians to predict more efficient treatments and prevention strategies for a given disease based on the genetic background of the patient. This approach has already been proposed for vaccines, but research is lagging behind the needs of society, and precision medicine is far from being implemented here. While vaccinomics concerns the effectiveness of vaccines, adversomics concerns their side effects. This area has great potential to address public concerns about vaccine safety and to promote increased public confidence, higher vaccination rates, and fewer serious adverse events in genetically predisposed individuals. The aim here is to explore the contemporary scientific literature related to the vaccinomic and adversomic aspects of the three most-controversial vaccines: those against hepatitis B, against measles, mumps, and rubella, and against human Papilloma virus. We provide detailed information on the genes that encode human leukocyte antigen, cytokines and their receptors, and transcription factors and regulators associated with the efficacy and safety of the Hepatitis B and Measles, Mumps and Rubella virus vaccines. We also investigate the future prospects of vaccinomics and adversomics of a COVID-19 vaccine, which might represent the fastest development of a vaccine ever.

APA, Harvard, Vancouver, ISO, and other styles

7

Scheifele, David W., Gordean L. Bjornson, William G. Meekison, Roland Guasparini, and Leslie A. Mitchell. "Evaluation ofHaemophilus influenzaeType B Conjugate Vaccine (Meningococcal Protein Conjugate) in Canadian Infants." Canadian Journal of Infectious Diseases 5, no. 2 (1994): 75–81. http://dx.doi.org/10.1155/1994/479313.

Full text

Abstract:

Objective: To assess adverse effects and immune responses with a three-dose series ofHaemophilus influenzaetype b meningococcal protein conjugate (PedvaxHIB or Hib.OMP) vaccine, including any immunological response alterations from concurrent administration with routine vaccines for infants.Design: Randomized, controlled trial with treatment group crossover for dose 3.Setting: Two public health units near Vancouver.Participants: One hundred and ten healthy infants eight to 14 weeks old were enrolled; 105 completed the study (95%).Interventions: All participants received two doses of diphtheria-pertussis-tetanus (dpt) vaccine (at two and four months of age) and one dose of measles-mumps-rubella (mmr) vaccine at 12 months. In each instance, Hib.OMP was given either concurrently in another limb or after a delay of two weeks (afterdpt) or four weeks (aftermmr).Main Outcome Measures: Adverse effects, particularly fever and local erythema, were monitored by parents for 72 h after each dose of Hib.OMP vaccine. Five blood samples were taken at prescribed intervals to assess responses to each dose of Hib.OMP and to selected other vaccine antigens.Main Results: Follow-up was obtained after all 322 doses of Hib.OMP. Local adverse effects were infrequent and mild: 13% had redness, 17% tenderness. Systemic effects in those given Hib.OMP alone included fever in 8%, irritability in 29%. Anti-polyribose-ribitol phosphate (prp) responses to Hib.OMP were not impaired by coadministration withdptormmrvaccines, nor were tetanus or diphtheria antitoxin levels or rubella or measles response rates affected. After two doses of Hib.OMP, 92% were seropositive and 64% had greater than 1.0 μg/mL of anti-prp. After three doses, 100% were seropositive and 82% exceeded 1.0 μg/mL.Conclusion: Hib.OMP vaccine was well tolerated, immunogenic and compatible with vaccines routinely given to infants in Canada.

APA, Harvard, Vancouver, ISO, and other styles

8

D'Souza, Jennifer, and Timothy Todd. "Measles-Mumps-Rubella Vaccine and the Development of Autism or Inflammatory Bowel Disease: The Controversy Should End." Journal of Pediatric Pharmacology and Therapeutics 8, no. 3 (July 1, 2003): 187–99. http://dx.doi.org/10.5863/1551-6776-8.3.187.

Full text

Abstract:

Vaccines have been administered to millions of individuals, usually infants and children, with few serious adverse effects. In 1998 a report suggested that there may be a link between the measles-mumps-rubella vaccine and the development of behavioral abnormalities (i.e., autism) and inflammatory bowel disease in children. This report generated considerable media and political attention, which many feared would result in a decreased willingness of parents to immunize their children against these contagious diseases. Over the past decade, an increasing number of healthcare practitioners have been credentialed to administer vaccinations. Therefore, it is imperative for all medical professionals to understand the controversy surrounding this issue and to be able to appropriately educate and advise parents accordingly. This review article evaluated the primary and secondary literature pertaining to this topic and concluded that the available epidemiological and scientific evidence does not support a causal association between the MMR vaccine and autism or inflammatory bowel disease.

APA, Harvard, Vancouver, ISO, and other styles

9

O'Brien, Timothy J. "Pediatric Immunizations: A Review." Journal of Pharmacy Practice 2, no. 1 (February 1989): 21–27. http://dx.doi.org/10.1177/089719008900200104.

Full text

Abstract:

Since Edward Jenner discovered that injecting cowpox virus into humans could prevent smallpox, the science of immunology has produced many vaccines that have virtually eradicated some of the worst childhood diseases known to mankind. Along with this great benefit, some vaccines carry with them potentially serious side effects. This review considers the mechanisms of immunology and how these are taken advantage of in vaccine production. The pharmacist is then acquainted with each of the vaccines used in childhood: measles, mumps, rubella (MMR); diphtheria, tetanus toxoids, and pertussis (DTP); oral polio vaccine (OPV); inactivated polio vaccine (IPV); and Hemophilus influenza type b vaccine (HIB). A review of each respective disease entity is considered along with each vaccines's method of production, immunization schedule, and adverse reactions. Some of the more controversial issues of vaccination are considered such as the use of live attenuated vaccines in human immunodeficiency virus (HIV) positive children and the inadvertent use of rubella vaccine in pregnant women. This report capitalizes on the most recent recommendations of the Immunization Practices Advisory Committee in order to provide the pharmacist with the most current information in the field of vaccine immunology today.

APA, Harvard, Vancouver, ISO, and other styles

10

Nofal, Ahmad, Reda Ezz El-arab, Mohamed Nasr, and Rania Alakad. "Intralesional Measles, Mumps, and Rubella Vaccine Versus Intralesional Candida Antigen in the Treatment of Common and Plantar Warts." Journal of Cutaneous Medicine and Surgery 25, no. 4 (February 3, 2021): 377–83. http://dx.doi.org/10.1177/1203475421991130.

Full text

Abstract:

Background Intralesional immunotherapy has been effectively used in the treatment of warts; however, comparative studies between different antigens are limited. Objective To evaluate the efficacy and safety of intralesional measles, mumps, and rubella (MMR) vaccine compared with intralesional Candida antigen for the treatment of multiple common and plantar warts. Methods Sixty-eight adult patients with multiple common and plantar warts were randomly assigned into two groups, each containing 34 patients. The first group received intralesional MMR vaccine, while the second group received intralesional Candida antigen. Each treatment was injected into the largest wart at 2-week intervals until complete clearance or for a maximum of 5 sessions. Results The overall therapeutic response was higher in the Candida antigen group (73.5%) compared with the MMR group (67.7%); however, the difference was not statistically significant. Complete clearance of common warts was higher in the Candida antigen group, while that of plantar warts was higher in the MMR group. Adverse effects were transient and well tolerated in both groups. No recurrence was detected during the 6-month follow-up period. Conclusion Intralesional MMR and intralesional Candida antigen showed comparable efficacy and safety in the treatment of common and plantar warts.

APA, Harvard, Vancouver, ISO, and other styles

More sources

Dissertations / Theses on the topic "Measles-Mumps-Rubella Vaccine $$x adverse effects"

1

Carlton, Rashad. "The Association between the Measles, Mumps, and Rubella Vaccine and the Development of Autism: A Meta-Analysis." [Tampa, Fla] : University of South Florida, 2008. http://purl.fcla.edu/usf/dc/et/SFE0002301.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Books on the topic "Measles-Mumps-Rubella Vaccine $$x adverse effects"

1

Callous disregard: Autism and vaccines -- the truth behind a tragedy. New York: Skyhorse Pub., 2010.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

2

Waging war on the autistic child: The Arizona 5 and the legacy of Baron von Munchausen. New York, NY: Skyhorse Pub., 2012.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

3

R, Stratton Kathleen, Institute of Medicine (U.S.). Board on Health Promotion and Disease Prevention., and Institute of Medicine (U.S.). Immunization Safety Review Committee., eds. Immunization safety review: Measles-mumps-rubella vaccine and autism. Washington, D.C: National Academy Press, 2001.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

4

Board on Health Promotion and Disease Prevention, Immunization Safety Review Committee, Kathleen Stratton, Alicia Gable, and Padma Shetty. Immunization Safety Review: Measles-Mumps-Rubella Vaccine and Autism. National Academies Press, 2001.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

5

Wakefield, Andrew J., and Jenny McCarthy. Callous Disregard: Austim and Vaccines - The Truth Behind a Tragedy. Skyhorse Publishing Company, Incorporated, 2011.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

6

Wakefield, Andrew J. Callous Disregard: Autism and Vaccines--The Truth Behind a Tragedy. Skyhorse, 2017.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

7

Defeating Autism: A Damaging Delusion. Routledge, 2008.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

8

Wakefield, Andrew J. Waging War on the Autistic Child: The Arizona 5 and the Legacy of Baron Von Munchausen. Skyhorse Publishing Company, Incorporated, 2016.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!